Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $330.92 in the prior trading day, Elevance Health Inc (NYSE: ELV) closed at $330.75, down -0.05%. In other words, the price has decreased by -$0.05 from its previous closing price. On the day, 1.67 million shares were traded. ELV stock price reached its highest trading level at $334.97 during the session, while it also had its lowest trading level at $329.625.
Ratios:
Our goal is to gain a better understanding of ELV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.71.
Leerink Partners Downgraded its Outperform to Market Perform on July 18, 2025, while the target price for the stock was maintained at $310.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 74477723648 and an Enterprise Value of 69520474112. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.53, and their Forward P/E ratio for the next fiscal year is 12.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 0.357 whereas that against EBITDA is 7.79.
Stock Price History:
The Beta on a monthly basis for ELV is 0.52, which has changed by -0.1579215 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $458.75, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is -0.82%, while the 200-Day Moving Average is calculated to be -7.95%.
Shares Statistics:
The stock has traded on average 1.79M shares per day over the past 3-months and 1402730 shares per day over the last 10 days, according to various share statistics. A total of 222.04M shares are outstanding, with a floating share count of 221.59M. Insiders hold about 0.29% of the company’s shares, while institutions hold 91.47% stake in the company. Shares short for ELV as of 1763078400 were 4041947 with a Short Ratio of 2.26, compared to 1760486400 on 2731969. Therefore, it implies a Short% of Shares Outstanding of 4041947 and a Short% of Float of 1.82.
Dividends & Splits
In the trailing 12 months, ELV’s forward annual dividend rate was 6.76, compared to 6.76 this year. Against a Trailing Annual Dividend Yield of 0.020427898. The stock’s 5-year Average Dividend Yield is 1.27. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-09-10 with an ex-dividend date of 2025-12-05. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
As of right now, 20.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $10.86, with high estimates of $13.99 and low estimates of $7.57.
Analysts are recommending an EPS of between $30.17 and $29.67 for the fiscal current year, implying an average EPS of $29.99. EPS for the following year is $27.3, with 22.0 analysts recommending between $31.59 and $24.5.
Revenue Estimates
11 analysts predict $49.63B in revenue for. The current quarter. It ranges from a high estimate of $51.04B to a low estimate of $48.4B. As of. The current estimate, Elevance Health Inc’s year-ago sales were $44.99BFor the next quarter, 11 analysts are estimating revenue of $50.83B. There is a high estimate of $51.84B for the next quarter, whereas the lowest estimate is $49.27B.
A total of 13 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $201.01B, while the lowest revenue estimate was $196.67B, resulting in an average revenue estimate of $197.93B. In the same quarter a year ago, actual revenue was $175.2BBased on 12 analysts’ estimates, the company’s revenue will be $205.02B in the next fiscal year. The high estimate is $213.85B and the low estimate is $197.52B.
